Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Rare Tumors
Главные авторы: Mahuad, Carolina Valeria, Repáraz, María de los Ángeles Vicente, Zerga, Marta E., Aizpurua, María Florencia, Casali, Claudia, Garate, Gonzalo
Формат: Artigo
Язык:Inglês
Опубликовано: PAGEPress Publications, Pavia, Italy 2016
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4935828/
https://ncbi.nlm.nih.gov/pubmed/27441079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/rt.2016.6266
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы